CA3172162A1 - Method and compositions for treating, preventing or limiting the occurrence of viral infection - Google Patents

Method and compositions for treating, preventing or limiting the occurrence of viral infection Download PDF

Info

Publication number
CA3172162A1
CA3172162A1 CA3172162A CA3172162A CA3172162A1 CA 3172162 A1 CA3172162 A1 CA 3172162A1 CA 3172162 A CA3172162 A CA 3172162A CA 3172162 A CA3172162 A CA 3172162A CA 3172162 A1 CA3172162 A1 CA 3172162A1
Authority
CA
Canada
Prior art keywords
composition
occurrence
viral infection
viral
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3172162A
Other languages
English (en)
French (fr)
Inventor
Daryl Lee Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Global Biolife Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3172162A1 publication Critical patent/CA3172162A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA3172162A 2020-03-16 2021-03-16 Method and compositions for treating, preventing or limiting the occurrence of viral infection Pending CA3172162A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062990168P 2020-03-16 2020-03-16
US62/990,168 2020-03-16
PCT/US2021/022538 WO2021188520A1 (en) 2020-03-16 2021-03-16 Method and compositions for treating, preventing or limiting the occurrence of viral infection

Publications (1)

Publication Number Publication Date
CA3172162A1 true CA3172162A1 (en) 2021-09-23

Family

ID=77768366

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3172162A Pending CA3172162A1 (en) 2020-03-16 2021-03-16 Method and compositions for treating, preventing or limiting the occurrence of viral infection

Country Status (9)

Country Link
US (1) US20230132782A1 (https=)
EP (1) EP4121040A4 (https=)
JP (1) JP2023518390A (https=)
KR (1) KR20230012469A (https=)
CN (1) CN115397410A (https=)
AU (1) AU2021236622A1 (https=)
BR (1) BR112022018504A2 (https=)
CA (1) CA3172162A1 (https=)
WO (1) WO2021188520A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230165831A1 (en) * 2021-11-19 2023-06-01 Impact Biolife Science, Inc. Method and composition for rendering cancer cells susceptible to treatment by targeted oncogenetic drivers
CN117462539A (zh) * 2023-12-26 2024-01-30 云南中医药大学 一种二氢黄酮醇型化合物的抗冠状病毒用途及制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1605335A (zh) * 2003-05-30 2005-04-13 任启生 含有二氢杨梅素和杨梅素的组合物用于抗病毒等药物
US8034838B2 (en) * 2008-05-29 2011-10-11 Daryl Lee Thompson Composition and method for the treatment of neurological disorders
CN101701245B (zh) * 2009-10-21 2013-06-19 中国科学院生物物理研究所 从中药中筛选sars冠状病毒主蛋白酶抑制剂的方法
US20140194500A1 (en) * 2013-01-08 2014-07-10 Kookmin University Industry Academic Cooperation Foundation Methods For Treating of SARS
US10383842B2 (en) * 2015-02-13 2019-08-20 Global Biolife Inc. Method and composition for preventing and treating viral infections
US12257231B2 (en) * 2015-02-13 2025-03-25 Global Biolife Inc. Method and composition for preventing and treating viral infections
US10123991B2 (en) * 2015-05-15 2018-11-13 Global Biolife Inc. Electrophilically enhanced phenolic compounds for treating inflammatory related diseases and disorders
US10966954B2 (en) * 2016-05-16 2021-04-06 Global Biolife Inc. Electrophilically enhanced phenolic compounds for treating inflammatory related diseases and disorders
US10987371B2 (en) * 2017-06-09 2021-04-27 Adaerata, Limited Partnership Methods of preventing or treating filovirus and flavivirus diseases
WO2019045677A1 (en) * 2017-08-28 2019-03-07 Global Biolife Inc. METHOD AND COMPOSITION FOR PREVENTING AND TREATING VIRAL INFECTIONS
CN113350330B (zh) * 2020-03-06 2023-04-14 中国科学院上海药物研究所 杨梅素类化合物在制备防治新冠肺炎药物中的应用
CN112546038A (zh) * 2020-11-19 2021-03-26 澳门科技大学 杨梅素在制备预防或治疗冠状病毒、流感病毒的药物中的应用
CN113244217A (zh) * 2021-06-25 2021-08-13 南开大学 二氢杨梅素在制备抑制新冠病毒或肺部纤维化的药物中的应用

Also Published As

Publication number Publication date
BR112022018504A2 (pt) 2022-11-29
WO2021188520A1 (en) 2021-09-23
US20230132782A1 (en) 2023-05-04
KR20230012469A (ko) 2023-01-26
CN115397410A (zh) 2022-11-25
JP2023518390A (ja) 2023-05-01
AU2021236622A1 (en) 2022-10-13
EP4121040A4 (en) 2024-07-17
EP4121040A1 (en) 2023-01-25

Similar Documents

Publication Publication Date Title
McKee et al. Candidate drugs against SARS-CoV-2 and COVID-19
US6410570B1 (en) Methods of inactivating a virus and controlling viral replication
Smee et al. Activities of oseltamivir and ribavirin used alone and in combination against infections in mice with recent isolates of influenza A (H1N1) and B viruses
KR20090130019A (ko) 톨-유사 수용체 3(ｔｌｒ３)의 제한적인 작용제
CA3172162A1 (en) Method and compositions for treating, preventing or limiting the occurrence of viral infection
Nyarko et al. A comparison analysis on remdesivir, favipiravir, hydroxychloroquine, chloroquine and azithromycin in the treatment of corona virus disease 2019 (COVID-19)-A Review
US6407125B1 (en) Pharmacological agent and method of treatment
WO2021023264A1 (zh) 用于治疗非洲猪瘟的药物组合物及其用途
Jitobaom et al. Synergistic anti-SARS-CoV-2 activity of repurposed anti-parasitic drug combinations
BR112022026874A2 (pt) Substância farmacêutica, uso, método de proteção de um indivíduo e vacina
Mohammad Immune response scenario and vaccine development for SARS-CoV-2 infection
Wang et al. Lactobacillus rhamnosus GG regulates host IFN-I through the RIG-I signalling pathway to inhibit herpes simplex virus type 2 infection
Baron et al. Innate antiviral defenses in body fluids and tissues
AU3702801A (en) Pharmacological agent comprising picolinic acid, fusaric acid and derivatives thereof
Gowen et al. Combinatorial ribavirin and interferon alfacon-1 therapy of acute arenaviral disease in hamsters
Smee et al. Inhibition of bluetongue and Colorado tick fever orbiviruses by selected antiviral substances
Turner The epidemiology, pathogenesis, and treatment of the common cold
Liu et al. The efficacy of an alternative mebendazole formulation in mice infected with Echinococcus multilocularis
Dianzani et al. Nonspecific defenses
Hassan et al. Monkeypox outbreak: an overview of potential therapeutic options
CN116942823A (zh) Ep300作为靶点在制备治疗急性肝损伤药物中的应用
Ramos‐Avila et al. Immunomodulatory role of chloroquine and pyrimethamine in Plasmodium yoelii 17XL infected mice
US6441009B1 (en) Agent and method of preventing and treating heavy metal exposure and toxicity
WO2009091435A2 (en) Methods of inhibiting viral infection
Alenius Inhibition of herpesvirus multiplication in guinea pig skin by antiviral compounds

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250902

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251103

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260102

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260202